| Cat. No. |
Product Name |
Information |
| PC-38426 |
Vepafestinib
RET inhibitor
|
Vepafestinib (TAS0953, HM06) is a next-generation RET inhibitor, potently inhibits recombinant WT RET kinase with IC50 of 0.33 nM, targets RET wild-type (WT) kinase and RET solvent front mutants (RETL730, RETV804 and RETG810). |
| PC-72475 |
BOS172738
RET inhibitor
|
BOS172738 (Zeteletinib, DS 5010) is a potent, selective oral RET kinase inhibitor with nanomolar potency against wtRET and RET mutations (Ki <1 nM), >300-fold selectivity against VEGFR2. |
| PC-72323 |
SYHA1815
RET inhibitor
|
SYHA1815 (SYHA-1815) is a novel potent, selective RET inhibitor, inhibits the kinase activity of RET wild type (IC50=0.9 nM) and V804 mutant (IC50=3.1 nM). |
| PC-72010 |
RET agonist BT44
RET agonist
|
RET agonist BT44 is a novel, specific RET agonist, promotes RET phosphorylation and selectively activates downstream cascades in the cells expressing GFL receptors. |
| PC-35286 |
GSK3179106
|
GSK3179106 (GSK-3179106, GSK 3179106) is a potent, selective, first-in-class and gut-restricted RET kinase inhibitor with IC50 of 0.4 and 11 nM in the biochemical assay and cellular assay respectively, 273-fold selectivity over KDR. |
| PC-35268 |
AD80
RET inhibitor
|
AD80 is a multikinase inhibitor that shows strong activity against human RET (IC50=4 nM), BRAF, S6K, and SRC, but has greatly reduced mTOR activity. |
| PC-63475 |
BLU-667
RET inhibitor
|
BLU-667 (Pralsetinib, BLU667) is a highly potent, selective, next generation RET inhibitor with IC50 of 0.3-0.4 nM for WT RET, RET mutants V804L, V804M, M918T and CCDC6-RET fusion. |
| PC-61590 |
NVP-AST487
RET inhibitor
|
NVP-AST487 (AST487) is a potent, oral bioavailable RET kinase inhibitor with IC50 of 0.88 uM, also inhibits KDR, Flt-4, Flt-3, c-Kit and c-Abl in vitro (IC50=0.1-1.2 uM). |
| PC-61589 |
BT-13
|
RET agonist BT13 is a novel small molecule GDNF receptor RET agonist, potently and selectively activates RET and its downstream intracellular signaling cascades in immortalized cells (EC50~20 uM). |
| PC-60209 |
LOXO-292
RET inhibitor
|
LOXO-292 (Selpercatinib, LOXO 292, LOXO292) is a potent, selective, orally available RET kinase inhibitor with IC50 of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M), and RET (G810R), respectively. |
| PC-45558 |
BBT-594
|
BBT-594 (NVP-BBT594) is a potent RET inhibitor that can impairs GDNF-RET signaling and GDNF-dependent growth of MCF7-LTED cells. |
| PC-20708 |
HSN608
RET inhibitor
|
HSN608 (HSN 608) is a potent inhibitor of RET solvent-front mutants, inhibits RET G810 solvent-front mutants and the V804M gatekeeper mutant with IC50 of <50 nM in cell culture, inhibits ABL1(T315I) with IC50 of 40.7 nM. |
